BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...

Mizuho Securities analyst Salim Syed has assigned their bullish stance on BBIO stock, giving a Buy rating on November 25.Don't Miss our Black ...

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look ...

The approval was based on positive results observed in the ATTRibute-CM Phase 3 study, where Attruby demonstrated a ...

Analyst Mani Foroohar from Leerink Partners maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report) and increased the price target to $47.00 from $46.00. Don't Miss our Black Friday ...

2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...

On Friday, BridgeBio Pharma Inc (BBIO) stock saw a modest uptick, ending the day at $23.42 which represents a slight increase of $0.18 or 0.77% from the prior close of $23.24. The stock opened at $23.

(BBIO), the company announced that its innovative drug, Attruby (acoramidis), has received FDA approval for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). This approval, granted by ...

On Friday, the FDA approved BridgeBio Pharma's Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer ...

In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other biotech stocks. Biotechnology stocks are among the most volatile in the market ...

BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...